CSIMarket Company Name, Ticker, Customers, else..
 
Alimera Sciences Inc  (NASDAQ: ALIM)
Other Ticker:  
 
 
Price: $5.5400 $-0.01 -0.180%
Day's High: $5.56 Week Perf: -0.18 %
Day's Low: $ 5.53 30 Day Perf: -0.89 %
Volume (M): 2,680 52 Wk High: $ 5.65
Volume (M$): $ 14,847 52 Wk Avg: $4.27
Open: $5.55 52 Wk Low: $2.77



 Market Capitalization (Millions $) 301
 Shares Outstanding (Millions) 54
 Employees 100
 Revenues (TTM) (Millions $) 98
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Alimera Sciences Inc
Alimera Sciences Inc is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company primarily focuses on diseases affecting the retina, such as diabetic macular edema and age-related macular degeneration. Alimera Sciences has developed an implantable drug delivery system called ILUVIEN, which is used to treat these retinal diseases. The company is dedicated to improving the lives of patients with vision impairments and providing innovative solutions in the field of ophthalmology. Alimera Sciences Inc is headquartered in Alpharetta, Georgia, and operates globally in various markets.


   Company Address: 6310 Town Square, Suite 400 Alpharetta 30005 GA
   Company Phone Number: 990-5740   Stock Exchange / Ticker: NASDAQ ALIM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -1.84%    
BMY        1.68% 
REGN   -4.93%    
SUPN        0.45% 
UTHR   -1.09%    
VRTX        2.09% 
• View Complete Report
   



Stocks on the Move

Alimera Sciences Faces Downgrade Amidst Merger Deal and Market Turbulence

Published Wed, Jun 26 2024 1:32 PM UTC

In recent news, Alimera Sciences Inc, a prominent player in the healthcare sector, has experienced a series of significant events that have impacted its financial outlook. These events include a downgrade by HC Wainwright & Co., a merger deal with ANI Pharmaceuticals Inc, and volatility in the market. This article aims to explore the implications of these events for Alimera ...
Shares

Assessing the Impact of Alimera Sciences' Inducement Grants on Company Shares

Published Tue, Jun 4 2024 8:30 PM UTC

Alimera Sciences Reports Inducement Grants: Assessing Impact on Company Shares
Alimera Sciences, a global pharmaceutical company focused on retinal health, recently announced the approval of inducement awards for five non-executive employees. These inducement awards, consisting of stock options under the 2024 Equity Inducement Plan, were granted to new or re-hired employ...
Alimera Sciences Inc

2. Alimera Sciences Inc Defies Adversity with Remarkable Revenue Growth Amidst Industry Challenges

Alimera Sciences Inc Shows Strong Revenue Growth Despite Challenging Market Conditions
In the first financial quarter of 2024, Alimera Sciences Inc, a global pharmaceutical company focused on retinal health and vision improvement, reported a loss of $-0.12 per share. This represents a significant improvement compared to the loss of $-0.71 per share recorded a year ago. Moreover, the company's deficit expanded slightly from $-0.05 per share in the previous quarter. Despite these setbacks, Alimera Sciences Inc managed to achieve notable revenue growth.
During the first quarter of 2024, Alimera Sciences Inc experienced a substantial increase in revenue, with a growth rate of 67.267%. The company's revenue soared to $22.66 million from $13.55 million in the corresponding quarter the previous year. However, there was a sequential revenue decline of -14.986% from $26.65 million. Nevertheless, Alimera Sciences Inc's revenue gains stand out, especially when compared to the contraction observed in many of its competitors within the Major Pharmaceutical Preparations sector.
Shares

Alimera Sciences Raises the Stakes: Inducement Grants Create Positive Ripples in Shares

Published Wed, Mar 20 2024 12:00 PM UTC

Alimera Sciences Announces Inducement Grants: What Does This Mean for the Company s Shares?
Alimera Sciences, a leading global pharmaceutical company specializing in retinal health and improving vision, recently made an important announcement regarding inducement grants. These grants were approved under the Alimera Sciences, Inc. 2024 Equity Inducement Plan and were give...
Clinical Study

Advancements in Radiation Retinopathy Treatment: ILUVIEN and Faricimab Injections Show Promise

Published Tue, Mar 19 2024 12:00 PM UTC

Radiation retinopathy is a severe side effect of radiation therapy, causing visual acuity loss and potentially leading to blindness. The groundbreaking research study conducted by the DRCR Retina Network, in partnership with Alimera Sciences, explores the efficacy of ILUVIEN and faricimab (6.0 mg) injections compared to observation in preventing visual acuity loss due to rad...






Alimera Sciences Inc's Segments
United States Segment    65.03 % of total Revenue
International Segment    34.97 % of total Revenue

  Alimera Sciences Inc Outlook

On March 7 2024 the Alimera Sciences Inc provided following guidance

Alimera Sciences Inc. has reported significant growth in its financial perform...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com